Inform colleague  Print page  

NatImmune A/S is a biotech company focusing on the development of protein-based therapeutics for the prevention and treatment of cancer and infectious diseases.

The lead product is based on replacement therapy of Mannan Binding Lectin (MBL) in patients carrying genetic pre-disposition to infections through a deficiency in the immune system. This project is partnered with ENZON Pharmaceuticals, Inc.

HAMLET, a protein-lipid complex, has potential in dermatology and areas such as actinic keratosis and genital warts. Moreover, the HAMLET technology has demonstrated physiological effects in case studies involving early-stage bladder cancer papillomas, as well as strong preclinical proof-of-concept in glioblastoma multiforme.

An antibody project aimed at a disease-specific target found only in Colorectal Cancers (CRC) and other adenocarcinomas is in the preclinical phase.